Table 1.
Baseline and Clinical Characteristics (n = 27)
| Age, median (IQR), y | 49 (40–54) |
|---|---|
| Male | 17 (63) |
| White/Caucasian | 25 (93) |
| Experiencing homelessness | 15 (56) |
| Substance use disordera | |
| People who inject drugs | 18 (67) |
| Noninjection drug use | 7 (26) |
| Alcohol use disorder | 6 (22) |
| Concomitant diseases | |
| Hepatitis C virus infection | 13 (48) |
| HIV infection | 4 (15) |
| Diabetes mellitus | 2 (7) |
| Cirrhosis | 1 (4) |
| Chronic kidney disease | 0 |
| Bacteremia | 25 (93) |
| Infection | |
| Documented bacteremia | |
| Uncomplicated bacteremia | 7 (26) |
| Complicated bacteremia | 4 (15) |
| Right-sided infective endocarditis | 7 (26) |
| Bone or joint infection with bacteremia | 4 (15) |
| Pneumonia with bacteremia | 2 (7) |
| Left-sided infective endocarditis | 1 (4) |
| Bone or joint infection without bacteremia | 2 (7) |
| Microorganisms | |
| Methicillin-susceptible Staphylococcus aureus | 12 (44) |
| Methicillin-resistant Staphylococcus aureus | 11 (41) |
| Polymicrobial | 4 (15) |
| MRSA and group A streptococci | 1 |
| MSSA and Streptococcus anginosus | 1 |
| Methicillin-resistant Staphylococcus epidermidis and group A streptococci | 1 |
| MRSA, Enterococcus durans or hirae, and alpha-hemolytic streptococci | 1 |
| Days of antibiotic therapy before dalbavancin administration, median (IQR) | 21 (8.5–35) |
| Hospital length of stay, actual, median (IQR) | 26 (10–34.5) |
| Hospital days averted per patient, median (IQR) | 7 (6–7) |
| 90-d inpatient re-admission, all-cause | 4 (15) |
| 90-d inpatient re-admission due to initial infection | 1 (4) |
| 90-d re-presentation to the emergency department/urgent care, all-cause | 10 (37) |
| 90-d re-presentation to the emergency department/urgent care due to initial infection | 0 |
| Follow-up appointment with either ID clinic, primary care provider, or other outpatient clinic to assess infection | 13/25 (52) |
| Loss to follow-up | 4 (15) |
| Potential dalbavancin-related adverse events | 2 (7) |
| 90-d mortality, all-cause | 0 |
| 90-d mortality due to initial infection | 0 |
| Clinical success | 22 (81) |
Data reported as No. (%) unless otherwise noted.
Abbreviations: ID, infectious diseases; IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
aCategories are not mutually exclusive.